000 03654nam a22004695i 4500
001 978-3-319-17972-8
003 DE-He213
005 20160405112901.0
007 cr nn 008mamaa
008 150425s2015 gw | s |||| 0|eng d
020 _a9783319179728
_9978-3-319-17972-8
024 7 _a10.1007/978-3-319-17972-8
_2doi
050 4 _aRC261-271
072 7 _aMJCL
_2bicssc
072 7 _aMED062000
_2bisacsh
082 0 4 _a614.5999
_223
245 1 0 _aResistance to Aromatase Inhibitors in Breast Cancer
_h[electronic resource] /
_cedited by Alexey Larionov.
264 1 _aCham :
_bSpringer International Publishing :
_bImprint: Springer,
_c2015.
300 _aXVI, 288 p. 56 illus., 27 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aResistance to Targeted Anti-Cancer Therapeutics,
_x2196-5501 ;
_v8
520 _aThe book brings together current knowledge about molecular and clinical aspects of resistance to aromatase inhibitors (AIs). The topics and features include: The history of development and clinical role of aromatase inhibitors in breast cancer. The structure and function of aromatase gene and protein, including tissue-specific splicing and regulation of the gene, crystal structure of the enzyme, functioning of its active site and structural basis for development of new aromatase inhibitors. Experimental and pre-clinical models of resistance to aromatase inhibitors (including cell lines and xenografts) as well as methods and results of measuring oestrogen concentrations in blood and tumour tissue of breast cancer patients. Diversity of molecular mechanisms of AI resistance, including (i) ligand-independent signalling through oestrogen receptor pathway, (ii) hypersensitivity to low concentrations of oestrogens, (iii) crosstalk with non-endocrine signalling (including PI3K/mTOR, IGF, GDNF and Myc pathways), (iv) involvement of oestrogen-induced apoptosis and tissue microenvironment (including inflammatory immune cells and adipocytes) as well as (v) the role of epigenetic mechanisms and pioneering factors in ER signalling and AI resistance. Molecular markers and multi-gene signatures to predict response to AIs, clinical trials aimed at preventing or overcoming resistance by combining AIs with novel targeted agents (including AI combinations with HER2, EGFR, mTOR, PI3K, Akt, CDK4/6, FGFR, HDAC, IGF-1, Src, proteosome- and angiogenic- targeting agents). A review of the effects and clinical indications of aromatase inhibitors beyond breast cancer. Many of the chapters provide extensive historical overviews to connect current knowledge with the history and inner logic of the field. The authors’ team includes world-leading experts, making the book an essential resource for scientists developing new treatments for breast cancer and for medics treating breast cancer patients with aromatase inhibitors.
650 0 _aMedicine.
650 0 _aCancer research.
650 0 _aDrug resistance.
650 0 _aMolecular biology.
650 1 4 _aBiomedicine.
650 2 4 _aCancer Research.
650 2 4 _aDrug Resistance.
650 2 4 _aMolecular Medicine.
700 1 _aLarionov, Alexey.
_eeditor.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9783319179711
830 0 _aResistance to Targeted Anti-Cancer Therapeutics,
_x2196-5501 ;
_v8
856 4 0 _uhttp://dx.doi.org/10.1007/978-3-319-17972-8
912 _aZDB-2-SBL
999 _c4046
_d4046